CRIS Current Research Information System

PINNA, ANTONIO DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.080
AS - Asia 20.006
EU - Europa 18.977
AF - Africa 1.636
SA - Sud America 1.395
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 13
Totale 73.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.868
SG - Singapore 6.191
GB - Regno Unito 5.548
CN - Cina 5.216
VN - Vietnam 4.777
DE - Germania 2.687
SE - Svezia 2.272
IT - Italia 2.223
HK - Hong Kong 1.472
IN - India 1.361
RU - Federazione Russa 1.211
UA - Ucraina 1.160
BR - Brasile 1.035
FR - Francia 869
IE - Irlanda 826
ZA - Sudafrica 503
EE - Estonia 427
NL - Olanda 421
CI - Costa d'Avorio 343
TG - Togo 341
CH - Svizzera 293
FI - Finlandia 289
JP - Giappone 255
SC - Seychelles 234
BG - Bulgaria 212
AR - Argentina 171
KR - Corea 167
JO - Giordania 161
NG - Nigeria 148
CA - Canada 128
BE - Belgio 108
AT - Austria 80
EC - Ecuador 78
PL - Polonia 71
ES - Italia 68
ID - Indonesia 62
IR - Iran 61
MX - Messico 56
GR - Grecia 53
BD - Bangladesh 51
TR - Turchia 39
RO - Romania 35
CL - Cile 32
CO - Colombia 23
HR - Croazia 22
IQ - Iraq 22
LB - Libano 22
PK - Pakistan 22
AU - Australia 21
LT - Lituania 21
MY - Malesia 21
UZ - Uzbekistan 20
PE - Perù 17
MA - Marocco 16
PY - Paraguay 16
CZ - Repubblica Ceca 12
EG - Egitto 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
DK - Danimarca 10
NO - Norvegia 10
UY - Uruguay 10
DO - Repubblica Dominicana 8
PH - Filippine 8
PT - Portogallo 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
EU - Europa 7
IL - Israele 7
AL - Albania 6
KE - Kenya 6
SK - Slovacchia (Repubblica Slovacca) 6
TH - Thailandia 6
TN - Tunisia 6
DZ - Algeria 5
ET - Etiopia 5
KZ - Kazakistan 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CR - Costa Rica 4
KH - Cambogia 4
MD - Moldavia 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
DM - Dominica 3
GE - Georgia 3
JM - Giamaica 3
KG - Kirghizistan 3
LK - Sri Lanka 3
PA - Panama 3
SI - Slovenia 3
TW - Taiwan 3
AM - Armenia 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
GA - Gabon 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
Totale 73.089
Salva come PNG Salva come JPEG
Città #
Southend 5.014
Singapore 4.014
Fairfield 3.993
Ashburn 3.072
Chandler 2.306
Woodbridge 1.988
Dong Ket 1.785
Houston 1.740
Wilmington 1.728
Seattle 1.603
Hong Kong 1.464
Cambridge 1.427
Santa Clara 1.226
Princeton 1.203
Ann Arbor 1.053
Dublin 775
Ho Chi Minh City 718
Beijing 704
Boardman 664
Jacksonville 658
Nanjing 557
Westminster 529
Hanoi 517
Padova 481
Hefei 446
Bologna 416
Berlin 364
Abidjan 343
Lomé 341
Los Angeles 337
Dallas 297
Saint Petersburg 268
Jinan 262
Bern 256
New York 248
Shenyang 247
Tokyo 246
Helsinki 243
San Diego 231
Buffalo 226
Munich 220
Sofia 210
Changsha 170
Nanchang 167
Hebei 165
Dearborn 164
Amman 161
Seoul 160
Redondo Beach 158
Turin 146
Milan 142
Mülheim 139
Florence 134
Medford 134
São Paulo 124
Tianjin 122
Abeokuta 118
Frankfurt am Main 116
Jiaxing 112
Menlo Park 112
Guangzhou 111
Brussels 104
Delhi 104
Bremen 100
Zhengzhou 98
Falls Church 93
Norwalk 93
Redmond 86
Haiphong 84
Shanghai 83
Redwood City 81
Hangzhou 79
Olalla 78
Des Moines 71
Da Nang 69
Phoenix 69
Ningbo 66
Mahé 63
Toronto 62
Haikou 60
Lanzhou 59
Falkenstein 58
Yubileyny 56
Chicago 53
London 52
Fuzhou 49
Taizhou 49
Vienna 48
Verona 46
Rome 43
Taiyuan 43
Biên Hòa 42
Bengaluru 40
Hải Dương 40
Bühl 39
Wuhan 39
Kunming 38
The Dalles 37
Turku 37
Warsaw 36
Totale 49.522
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 488
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 464
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 373
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 321
A comprehensive analysis on expected years of life lost due to pancreatic cancer 278
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 270
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 265
Prognostic criteria for postoperative mortality in 170 patients undergoing major right hepatectomy 259
Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy 254
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 243
A new liver transplant priority for patients with hepatocellular carcinoma. 236
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 235
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 230
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 228
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 227
Burnout and psychological distress between surgical and non-surgical residents 225
Antifungal prophylaxis in liver transplant recipients: one size does not fit all 224
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 222
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 220
Infections in liver and lung transplant recipients: A national prospective cohort 219
Combined liver-kidney transplantation: the experience of the University of Bologna and the case of preoperative positive cross-match. 217
Surgical therapy for hepatolithiasis: a Western experience. 216
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 214
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 214
Anticorpi anti-HLA preformati e Trapianto Combinato Rene-Fegato. Caso clinico. 211
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 208
Long-term endoscopic follow-up in small bowel transplant recipients: single-center series. 204
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 203
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 202
A partnership model between high- And low-volume hospitals to improve results in hepatobiliary pancreatic surgery 201
Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. 199
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 199
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 199
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 198
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 196
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 196
Bacterial translocation in adult small bowel transplantation 196
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 196
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? 196
Combined liver–dual kidney transplant: Role in expanded donors 195
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 193
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 192
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 192
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 192
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 191
Coping strategies in intestinal transplantation 190
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 190
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 190
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 190
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 189
Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy 189
Combined heart and liver transplantation for familial amyloidotic polyneuropathy. 188
A new liver extracorporeal device (LEONARDO) to treat swine with post-resection acute liver failure 188
Abdominal wall defect repair with biological prosthesis in transplanted patients: single center retrospective analysis and review of the literature 188
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 187
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 187
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. 187
Abdominal wall transplantation with microsurgical technique 187
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 187
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 186
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 186
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 185
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 185
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 185
COMBINED KIDNEY LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE 184
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 184
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 183
ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. 183
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 183
Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies? 182
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 181
Multimodal Surgical Approach for Adult Patients With Chronic Intestinal Pseudo-Obstruction: Clinical and Psychosocial Long-term Outcomes 181
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 180
Analysis of 80 dual-kidney transplantations: a multicenter experience. 180
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 179
Combined liver-kidney transplantation-s. Orsola experience: nephrological aspects. 179
Efficacy of MELD score in predicting survival after liver retransplantation. 178
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 178
T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam 178
Increase of portal blood oxygenation by artero-venous shunt in diabetic rats 178
Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation 177
Application of a fluorescent PCR method for molecular diagnosis of posttransplant lymphoproliferative disorders on routine tissue sections. 177
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. 176
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 175
A simplified technique for the en-bloc procurement of abdominal organs that is suitable for pancreas and small bowel transplantation. 175
Using Elderly Donors in Liver Transplantation. 174
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 174
A Multicentric Study on Double Kidney Transplantation 174
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 174
A prospective multi-center randomized clinical study to compare the efficacy of ertapenem 3 days versus ampicillin-sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection 173
Combined heart-liver transplantation: A single-center experience 173
Combined Liver-Kidney Transplantation With Preformed Anti-HLA Antibodies: A Case Report. 173
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 172
Combined liver transplants: main characteristics from the standpoint of anesthesia and support in intensive care 171
In Reply 171
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. 171
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 171
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 170
Analysis of cardiovascular, acid-base status, electrolyte and coagulation changes during small bowel transplantation 170
Totale 20.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.609
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.609
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.087 0 0 0 0 0 341 114 394 632 371 333 2.902
2021/20229.997 1.003 403 591 794 955 535 236 630 356 507 2.252 1.735
2022/202310.182 1.139 1.611 579 1.339 621 704 268 551 1.767 241 859 503
2023/20242.442 201 478 121 263 170 507 117 173 83 171 71 87
2024/202510.237 425 1.858 822 764 1.896 521 608 254 123 652 258 2.056
2025/202612.461 2.407 1.967 2.222 1.663 2.735 1.467 0 0 0 0 0 0
Totale 74.299